Biopharmaceuticals: recent trends and likely directions: Recent approvals and likely directions

Gary Walsh

doi:10.1016/j.tibtech.2005.07.005

Biopharmaceuticals: recent trends and likely directions: Recent approvals and likely directions

Gary Walsh

Department of Chemical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Some 160 biopharmaceuticals have now gained medical approval and several hundred are in the pipeline. Most are protein-based, although two nucleic acid-based products are now on the US/European market. An increasing proportion of approvals are engineered in some way and advances in alternative production systems and delivery methods will also likely impact upon the approvals profile over the remainder of this decade.

Original language	English (Ireland)
Pages (from-to)	553-558
Number of pages	6
Journal	Trends in Biotechnology
Volume	23
Issue number	11
DOIs	https://doi.org/10.1016/j.tibtech.2005.07.005
Publication status	Published - Nov 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.tibtech.2005.07.005

Cite this

@article{a91df2847002452096efc9fbd348c8b1,

title = "Biopharmaceuticals: recent trends and likely directions: Recent approvals and likely directions",

abstract = "Some 160 biopharmaceuticals have now gained medical approval and several hundred are in the pipeline. Most are protein-based, although two nucleic acid-based products are now on the US/European market. An increasing proportion of approvals are engineered in some way and advances in alternative production systems and delivery methods will also likely impact upon the approvals profile over the remainder of this decade.",

author = "Gary Walsh",

year = "2005",

month = nov,

doi = "10.1016/j.tibtech.2005.07.005",

language = "English (Ireland)",

volume = "23",

pages = "553--558",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Biopharmaceuticals: recent trends and likely directions

T2 - Recent approvals and likely directions

AU - Walsh, Gary

PY - 2005/11

Y1 - 2005/11

N2 - Some 160 biopharmaceuticals have now gained medical approval and several hundred are in the pipeline. Most are protein-based, although two nucleic acid-based products are now on the US/European market. An increasing proportion of approvals are engineered in some way and advances in alternative production systems and delivery methods will also likely impact upon the approvals profile over the remainder of this decade.

AB - Some 160 biopharmaceuticals have now gained medical approval and several hundred are in the pipeline. Most are protein-based, although two nucleic acid-based products are now on the US/European market. An increasing proportion of approvals are engineered in some way and advances in alternative production systems and delivery methods will also likely impact upon the approvals profile over the remainder of this decade.

UR - https://www.scopus.com/pages/publications/26944499416

U2 - 10.1016/j.tibtech.2005.07.005

DO - 10.1016/j.tibtech.2005.07.005

M3 - Article

C2 - 16051388

AN - SCOPUS:26944499416

SN - 0167-7799

VL - 23

SP - 553

EP - 558

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 11

ER -

Biopharmaceuticals: recent trends and likely directions: Recent approvals and likely directions

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this